Literature DB >> 27545739

Mastocytosis.

Ayesha Abid1, Michael A Malone2, Katherine Curci2.   

Abstract

Mastocytosis is a rare disease caused by excessive production of mast cells. Clinical presentation is variable, often based on the type of mastocytosis, but in all types of mastocytosis there seems to be an increase in the risk of anaphylaxis. Systemic mastocytosis is diagnosed based on bone marrow biopsy. Treatment is variable based on the type of mastocytosis, but trigger avoidance and anaphylaxis treatment are mainstays. There are no therapies that change the natural course of mastocytosis. For cutaneous mastocytosis, treatment is conservative and aimed at symptom relief.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cutaneous mastocytosis; Diagnosis; Masocytosis; Pathophysiology; Review; Systemic mastocytosis; Treatment; Update

Mesh:

Substances:

Year:  2016        PMID: 27545739     DOI: 10.1016/j.pop.2016.04.007

Source DB:  PubMed          Journal:  Prim Care        ISSN: 0095-4543            Impact factor:   2.907


  6 in total

1.  Avapritinib: A Selective Inhibitor of KIT and PDGFRα that Reverses ABCB1 and ABCG2-Mediated Multidrug Resistance in Cancer Cell Lines.

Authors:  Chung-Pu Wu; Sabrina Lusvarghi; Jyun-Cheng Wang; Sung-Han Hsiao; Yang-Hui Huang; Tai-Ho Hung; Suresh V Ambudkar
Journal:  Mol Pharm       Date:  2019-06-04       Impact factor: 4.939

2.  Successful Imatinib Treatment for Systemic Mastocytosis Associated With Myelodysplastic/Myeloproliferative Neoplasm: Report of a Case and Literature Review.

Authors:  Enrico Barozzi; Cristina Bucelli; Federica Irene Grifoni; Umberto Gianelli; Alessandra Iurlo; Daniele Cattaneo
Journal:  Front Oncol       Date:  2022-01-12       Impact factor: 6.244

3.  Lenalidomide-induced autoimmune enteropathy complicating treatment of multiple myeloma with concurrent systemic mastocytosis.

Authors:  Stephanie Lakritz; Peter A Forsberg; Daniel W Sherbenou; Tomer M Mark
Journal:  Clin Case Rep       Date:  2022-09-19

4.  How persons with systemic mastocytosis describe the time between symptom onset and receiving diagnosis.

Authors:  Kerstin Hamberg Levedahl; Annika Nilsson; Birgitta Johansson; Mariann Hedström
Journal:  Prim Health Care Res Dev       Date:  2022-09-07       Impact factor: 1.792

Review 5.  [Medical apps-possibilities for pruritus].

Authors:  B Schuster; M Dugas; A Zink
Journal:  Hautarzt       Date:  2020-07       Impact factor: 0.751

6.  Solitary mastocytoma presenting at birth.

Authors:  Non Hyeon Ha; Yoo Jung Lee; Myong Chul Park; Il Jae Lee; Sue Min Kim; Dong Ha Park
Journal:  Arch Craniofac Surg       Date:  2018-04-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.